FDA-approved Treatments
Experimental Treatments
Top New Articles
 Google Custom Search

New AmFAR Survey Reveals HIV Positive Women Still Face Stigma

More than 2 decades into the HIV/AIDS epidemic, HIV positive women continue to face considerable stigma, according to a survey recently released by amFAR, the Foundation for AIDS Research.

The survey was conducted online in March and April of 2007 by Harris Interactive, and included nearly 5000 participants who answered questions about their attitudes toward women with HIV.

Below is the edited text of a press release from amFAR announcing the results. The group also held a media briefing on March 31. A PowerPoint presentation of slides from the briefing is available online at http://www.amfar.org.

Stigma Clings Stubbornly to Women
Living With HIV/AIDS

Washington, D.C. (March 31, 2008) -- HIV-positive women in the United States face strikingly high levels of stigma, according to survey results released today by amfAR, The Foundation for AIDS Research.

The results of the survey reveal pervasive negative views of HIV-positive women and a high level of discomfort in interacting with them. Many of the responses display a lack of knowledge of how HIV is transmitted and misplaced fear of contracting the virus that indicate a pressing need to scale up prevention education efforts.

Sixty-eight percent [68%] of respondents indicated that they would be somewhat or not at all comfortable with an HIV-positive woman as their dentist; 59 percent said they would be somewhat or not at all comfortable with an HIV-positive woman serving as their childcare provider; and 57 percent said they would be somewhat or not at all comfortable having a female physician who is HIV-positive. One in five respondents would be somewhat or not at all comfortable having a close friend who is HIV positive.

Only 14 percent of respondents felt that HIV-positive women should have children. Currently medication exists to prevent mother-to-child transmission of HIV.

The survey also demonstrates significant differences in how Blacks, Hispanics, and Caucasians perceive HIV/AIDS and the risk of acquiring it. Of those who know someone with HIV or AIDS, Blacks (34 percent) and Hispanics (32 percent) are much more likely to have a family member with HIV/AIDS than Caucasians (13 percent).

Insights were also gained into public attitudes about HIV testing. Nearly 40 percent were sure they had not been tested for HIV. A majority (80 percent) of these respondents indicated that they did not need a test either because they “knew” they did not have HIV or because they didn’t think they needed to be tested.

However, respondents overwhelmingly supported expanded HIV testing and 65 percent support making HIV testing part of standard routine healthcare. This acceptance may be partially linked to the belief that HIV testing occurs more frequently than it does, with 67 percent mistakenly assuming that they are automatically screened for HIV when they are tested for other sexually transmitted infections. Fifty percent believed that women are automatically tested during prenatal exams.

The survey draws much needed attention to the plight of women living with HIV/AIDS. Forty-six percent of people with HIV/AIDS worldwide -- about 15.4 million -- are women and girls. In the United States, women account for 27 percent of new AIDS diagnoses, up from only eight percent in 1985. Both domestically and internationally, women continue to face widespread social and gender inequalities that can make it difficult for them to reduce their risk of HIV infection. In addition, women are biologically more susceptible to HIV infection than men.

“In the minds of many people, AIDS in the United States is no longer a crisis,” said Rear Admiral Susan J. Blumenthal, MD, MPA, amfAR’s senior policy and medical advisor and former deputy assistant secretary for women’s health in the U.S. Department of Health and Human Services. “Complacency has obscured the changing face of the epidemic and the dramatic rise in HIV infections in women over the past 25 years. These results should serve as a wake-up call for action across all sectors of society. We need to intensify efforts for science-based education and policy to shatter the stigma that has surrounded this disease for all too long.”

The online survey, conducted by Harris Interactive for amfAR, questioned nearly 5,000 respondents ages 18-44 and covered HIV risk and responsibility, impact of gender-based violence, and women’s access to healthcare and health information, as well as attitudes towards HIV-positive women. The survey was made possible by grants from Broadway Cares /Equity Fights AIDS and the M.A.C AIDS Fund.

“Many women erroneously believe that they are not at risk for HIV,” said Hofmann, who is HIV positive. “This is why we are seeing the rate of new infections for women rise significantly in America. While many women accept that they could potentially become pregnant from even just one act of unprotected sex, they feel that they would have to do something ‘extraordinary’ to contract HIV, like be excessively promiscuous or be involved with people the likes of whom they don't think they would encounter in their everyday world.”

Brown said, “I take seven pills daily that make me sick to my stomach. I experience nausea, diarrhea, vomiting and the worst of all mood swings. But yet it is still not the worst part of having HIV. It is the stigma.”

About amfAR

amfAR, The Foundation for AIDS Research, is one of the world’s leading nonprofit organizations dedicated to the support of AIDS research, HIV prevention, treatment education, and the advocacy of sound AIDS-related public policy. Since 1985, amfAR has invested nearly $275 million in its programs and has awarded grants to more than 2,000 research teams worldwide. For more information about amfAR, visit www.amfar.org.

About Harris Interactive

Harris Interactive is a global leader in custom market research. With a long and rich history in multimodal research that is powered by our science and technology, we assist clients in achieving business results. Harris Interactive serves clients globally through our North American, European and Asian offices and a network of independent market research firms. For more information, please visit www.harrisinteractive.com.

Methodology

This survey was conducted online within the United States by Harris Interactive on behalf of amfAR between March 22 and April 17, 2007, among 4831 people ages 18 to 44 who were willing to disclose their race. Sample included an oversample of Blacks and Hispanics. No estimates of theoretical sampling error can be calculated; a full methodology is available.

4/04/08

Source
amFAR.
Stigma Clings Stubbornly to Women Living With HIV/AIDS. Press release. March 31, 2008.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Protease Inhibitors (PIs)
Note: Most PIs are now used
in combination with low-dose
ritonavir (Norvir)
Agenerase
Agenerase (amprenavir)
Aptivus
Aptivus (tipranavir)
Crixivan
Crixivan (indinavir)
Invirase
Invirase (saquinavir )
Kaletra
Kaletra (lopinavir/ritonavir)
Lexiva
Lexiva (fosamprenavir)
Norvir
Norvir (ritonavir)
Prezista
Prezista (darunavir)
Reyataz
Reyataz (atazanavir)
Viracept
Viracept (nelfinavir)
Nucleoside / Nucleotide
Reverse Transcriptase
Inhibitors (NRTIs)
Combivir
Combivir (zidovudine + lamivudine)
Epivir
Epivir (lamivudine; 3TC)
Emtriva
Emtriva (emtricitabine; FTC)
Epzicom
Epzicom (abacavir + lamivudine)
Retrovir
Retrovir (zidovudine; AZT)
Trizivir
Trizivir (abacavir + zidovudine +lamivudine)
Truvada
Truvada  (tenofovir + emtricitabine)
Videx
Videx (didanosine; ddI)
Viread
Viread (tenofovir)
Zerit
Zerit (stavudine; d4T)
Ziagen
Ziagen (abacavir)
non Nucleoside 
Reverse Transcriptase
 Inhibitors
(nNRTIs)
Rescriptor
Intelence (etravirine)
Rescriptor
Rescriptor (delavirdine)
Sustiva
Sustiva (efavirenz)
Viramune
Viramune (nevirapine)
Entry / Fusion Inhibitors
Fuzeon (enfuvirtide)
Selzentry/Celsentri ( maraviroc)
Fixed-dose Combinations
Atripla
Atripla (efavirenz + emtricitabine + tenofovir)
Combivir
Combivir (zidovudine + lamivudine)
Trizivir
Trizivir (abacavir + zidovudine + lamivudine)
Truvada
Truvada (tenofovir + emtricitabine)
Integrase Inhibitors
Isentress (raltegravir)